Processa Pharmaceuticals Business Update
Processa Pharmaceuticals issued a stockholder letter outlining its strategic shift toward immunological and inflammatory (I&I) diseases following its July acquisition of Vidya Therapeutics. The company highlighted the advancement of its lead BTK inhibitor candidate, VT-7208, into Phase 2 development for food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis, supported by approximately $183.3 million in net cash proceeds.